Open AccessLyell-Like Acute Graft-Versus-Host-Disease
Author(s) -
Caroline de Lorenzi,
Yassaman Alipour Tehrany,
Sébastien Menzinger
Publication year - 2021
Language(s) - English
DOI - 10.47363/jdmrs/2021(2)131
Subject(s) - etanercept , medicine , graft versus host disease , refractory (planetary science) , disease , tissue typing , host (biology) , surgery , immunology , dermatology , tumor necrosis factor alpha , biology , ecology , astrobiology , human leukocyte antigen , antigen
Stage IV acute cutaneous graft-versus-host-disease (GVHD) is nowadays rarely seen due to tissue typing done before transplant. The first line treatment for acute GVHD grade II-IV is systemic corticosteroids. However, although there is no consensus for refractory cases, literature report diverse therapies to be effective. We report the case of a 34 year-old patient with refractory acute cutaneous graft-versus-host-disease stage IV successfully treated with etanercept